Jared Whitlock

Features editor @endpts.

Reach out privately on Signal: jaredwhitlock.73

[Jared Whitlock @Jared_Whitlock]

For families, a $2.1M medicine can feel like both a miracle and an out-of-reach reality.

Now, biotechs in China are racing to develop lower-cost alternatives:

https://t.co/dwzX2DHwml

[Matthew Herper @matthewherper]

Remembering J. Craig Venter: a relentless scientist who changed biotech — and was all too easily misunderstood

https://t.co/5uURri5wsM via @statnews

[Matthew Herper @matthewherper]

I'm sad to learn that J. Craig Venter, a key figure in modern genomics and an inveterate troublemaker, passed away.

Craig was very important to the study of human genetics and the biotechnology industry. He also had an impact on my career. The pitch that led @michaelnoer to hire me at Forbes in 2000 was about Venter's company, Celera Genomics, and its work on the mouse genome.

Seventeen years, later, Michael edited a cover story I wrote about Venter for Forbes.

[Ryan Cross the Science Boss @RLCscienceboss]

Must read story from @antonioregalado about a biotech that wants to make brainless clones as a personal source of organ donation or even body transplant. They pitched themselves to me as an alternative to animal models company. That wasn't the full story. https://t.co/qlcEDaDfet

[Brent Crane @bcamcrane]

Theia Group set out to revolutionize space-based surveillance. Its enigmatic founder, a former NASA engineer, envisioned nothing less then "Google for the physical world," he told me from jail.

My @BW investigation into Theia's dramatic rise & fall:
https://t.co/Rn345BJF8f

[Jared Whitlock @Jared_Whitlock]

Reporting here: https://t.co/FFh2nIBM1f

[Jared Whitlock @Jared_Whitlock]

ICYMI: Multimillion-dollar gene therapies weren’t supposed to face competition. China has other plans

[Drew Armstrong @ArmstrongDrew]

China competition is coming for the US's multimillion-dollar gene therapies -- a must-read from @Jared_Whitlock about what's happening there and how it will affect access around the world:

https://t.co/F7KaMv3Kkp

[Jared Whitlock @Jared_Whitlock]

Multimillion-dollar gene therapies weren’t supposed to face competition. China has other plans

My latest feature for @endpts, complete with data analysis.

https://t.co/FFh2nIBM1f

[John Carroll @JohnCendpts]

Did the FDA’s individualized therapy guidance put a spike in the heart of a startup biotech? Fake news, says the HHS. Yeah, it did, says an insider. Exclusive from @RLCscienceboss and @Jared_Whitlock
https://t.co/IN9o4VIp03

[Jason Mast @Jasonmmast]

EveryOne Medicines shuts down, ending custom cure venture that banked on new FDA pathway

https://t.co/NTTjuBqcX0

[Jared Whitlock @Jared_Whitlock]

Exclusive: EveryOne Medicines shuts down, ending custom cure venture that banked on new FDA pathway

From @RLCscienceboss and me:

https://t.co/NTUXXejm0x

[Brent Crane @bcamcrane]

Hey everyone! I'm starting a monthly newsletter on @Substack of curated longform journalism recommendations. I'll be highlighting the stories that've stuck with me the most each month + two books & a podcast. 1st post here. Please subscribe and share! https://t.co/8P1Fqeyfbj

[Jared Whitlock @Jared_Whitlock]

After rallying, Grail's cancer test faces new uncertainty due to UK study

My latest via @endpts:

https://t.co/KSGAqhAtzT

[Jared Whitlock @Jared_Whitlock]

A Chinese biotech says its gene therapy slowed aggressive brain cancer in an early human test, but the debated approach is already drawing skepticism from some researchers.

My latest. @endpts

https://t.co/pP8eY04NgD

[Lizzy Lawrence @LizzyLaw_]

Honored to have won a George Polk award for my coverage of the turmoil at FDA last year. The STAT team was also recognized for reporting on the Trump admin's impact on health and science. https://t.co/D3bp4J5xrr

[Lei Lei Wu @leilei_wuu]

With a valuation of about $61 billion, Hengrui is now larger than Takeda and Bayer.

But there’s still one big item on its bucket list: selling its own treatments outside of China. My story in @endpts:

https://t.co/lc179v8i13

[Endpoints News @endpts]

At #JPM26, pharma leaders said the US should focus on fixing its own biopharma system, not slowing China’s rise in drug development. https://t.co/3DZY6FMDHG

[Jared Whitlock @Jared_Whitlock]

Dispatch from #JPM2026:

Drugmakers and investors want US reforms, not to slow down China

https://t.co/s3zz2mLqik

[Amber Tong @AmberTongPW]

You know the China biotech story is here to stay when Endpoints starts hiring in Hong Kong. Exciting opportunity!

[Max Bayer @maxonwifi]

Pre-JPM news flow update: The embargoes are so plentiful that our copy editor is drawing filed stories from a hat.